State Street Corp. Amends BioCryst Pharma Stake Filing
Ticker: BCRX · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 882796
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amended-filing, passive-investment
TL;DR
**State Street Corp. still holds BioCryst stock, signaling continued institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 24, 2024, indicating its ownership of BioCryst Pharmaceuticals Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, confirming their continued significant, but passive, investment in BioCryst. For investors, this means a large institutional holder maintains its position, which can signal confidence in the company's long-term prospects, potentially providing a stable base for the stock.
Why It Matters
This filing confirms a major institutional investor, State Street Corporation, continues to hold a significant stake in BioCryst Pharmaceuticals, which can be a positive signal of institutional confidence for current and prospective shareholders.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate risk or significant change in company fundamentals.
Analyst Insight
Investors should view this as a routine update confirming continued institutional interest, rather than a signal for immediate action. It reinforces that a major financial player sees value in holding BioCryst shares.
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- BioCryst Pharmaceuticals Inc. (company) — the subject company whose stock is being reported
- 09058V103 (other) — CUSIP number for BioCryst Pharmaceuticals Inc. common stock
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
Forward-Looking Statements
- State Street Corporation will maintain a significant, passive stake in BioCryst Pharmaceuticals Inc. for the foreseeable future. (State Street Corporation) — high confidence, target: 12/31/2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amended Schedule 13G filing under the Securities Exchange Act of 1934, as indicated by 'FORM TYPE: SC 13G/A' and 'AMENDED FILING' in the document.
Who is the reporting person in this filing?
The reporting person is STATE STREET CORPORATION, as explicitly stated under '1. NAME OF REPORTING PERSON: STATE STREET CORPORATION'.
What is the subject company whose securities are being reported?
The subject company is BIOCRYST PHARMACEUTICALS INC, identified as 'NAME OF ISSUER: BIOCRYST PHARMACEUTICALS INC'.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the common stock of BioCryst Pharmaceuticals Inc. is 09058V103, as listed under 'CUSIP NUMBER: 09058V103'.
What was the date of the event that required this filing?
The date of the event which required this filing was December 31, 2023, as stated under 'DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT: 12/31/2023'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).